CohBar Inc (NASDAQ:CWBR) Stock Gains Further Momentum: Are You Excited?

Clinical-stage biopharmaceutical firm developing mitochondria-based therapeutics to treat chronic diseases and extend healthy lifespan, CohBar Inc (NASDAQ:CWBR) saw stock prices zoom by 26% on August 11, 2021. Investors cheered on the firm’s topline results from the multi-center, randomized, placebo-controlled Phase 1a/1b clinical study of CB4211, under development for nonalcoholic steatohepatitis and obesity.

According to the result, the CB4211 was well-tolerated with no adverse events. The results show that only adverse events occurred in >10% of subjects receiving CB4211 in the four-week Phase 1b portion.

Dr.Rohit Loomba, MD, MHSc, Professor of Medicine, Director, NAFLD Research Center, and Director of Hepatology, University of California at San Diego, said that the results are promising and show a good reduction in both serum ALT and AST relative to placebo. Loomba added that the improvements in serum are key predictors of histologic response.

Dr. Joseph Sarret, CohBar’s Chief Executive Officer, said that the company is optimistic about the outcomes of its first human trial of CB4211. Sarret added that it validates the company’s novel approach to harnessing the mitochondrial genome as an important source of therapeutic peptides to treat serious systemic diseases.

CB4211, the first mitochondria-based therapeutic, has entered clinical testing and is an emerging class of drug.